Radotinib

Radotinib is a drug used in the treatment of chronic myeloid leukemia (CML), a type of cancer that starts in certain blood-forming cells of the bone marrow. It is a second-generation tyrosine kinase inhibitor, which works by blocking certain proteins that can lead to the development of cancer cells.

Mechanism of Action

Radotinib inhibits BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). By doing so, it prevents the proliferation of cancer cells and induces apoptosis, or programmed cell death.

Clinical Use

Radotinib is approved for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive (Ph+) CML in patients who are resistant to or intolerant of at least one prior therapy, including imatinib.

Side Effects

Common side effects of radotinib include nausea, vomiting, diarrhea, and headache. Serious side effects may include myelosuppression, hepatotoxicity, and cardiac toxicity.

Development and Approval

Radotinib was developed by Il-Yang Pharm. Co., Ltd., a South Korean pharmaceutical company. It was approved for use in South Korea in 2012.

See Also

• Chronic myeloid leukemia
• Tyrosine kinase inhibitor
• BCR-ABL

• 
  Radotinib